The holistic management and the contribution of critical care to the successful management of the life-threatening condition of Fournier’s Gangrene in patients prescribed SGLT2 inhibitors is described in this paper with the aid of a case report. A gentleman in his 70s, prescribed empagliflozin, an SGLT2 inhibitor for managing his diabetes and heart failure, presented in a moribund condition to the Emergency Department. The combination of his comorbidities and medication management created an environment that increased his risk of developing the life threatening condition of Fournier’s gangrene, which was managed successfully. We present the many considerations that are important for a successful outcome of this condition in the setting of critical care. A whole system approach with a recognition of the risks of SGLT2 inhibitor therapy is key to the successful management of Fournier’s gangrene in critical care.